Risk of complications from bone metastases in breast cancer: implications for management
- 31 March 2000
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 36 (4), 476-482
- https://doi.org/10.1016/s0959-8049(99)00331-7
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 1999
- A high incidence of vertebral fracture in women with breast cancerBritish Journal of Cancer, 1999
- Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.Journal of Clinical Oncology, 1998
- Clinical course and prognostic factors following bone recurrence from breast cancerBritish Journal of Cancer, 1998
- Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.Journal of Clinical Oncology, 1997
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesThe New England Journal of Medicine, 1996
- Bisphosphonates: mechanisms of action.JCI Insight, 1996
- Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.Journal of Clinical Oncology, 1996
- Bone and cancer: Pathophysiology and treatment of metastasesBone, 1995
- Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, SwitzerlandCancer, 1977